-
Saxagliptin, sold
under the
brand name Onglyza, is an oral
hypoglycemic (anti-diabetic drug) of the
dipeptidyl peptidase-4 (DPP-4)
inhibitor class. Early...
- extended-release, is
called Xigduo XR. In July 2016, the fixed-dose
combination of
saxagliptin and
dapagliflozin was
approved for
medical use in the
European Union...
- with
metformin include a sitagliptin/metformin
combination (Janumet), a
saxagliptin/metformin
combination (Kombiglyze XR, Komboglyze), and an alogliptin/metformin...
- Dapagliflozin/
saxagliptin/metformin, sold
under the
brand name
Qternmet XR
among others, is a fixed-dose
combination anti-diabetic
medication used as...
-
Vildagliptin (EU
approved 2007,
marketed in the EU by
Novartis as Galvus)
Saxagliptin (FDA
approved in 2009,
marketed as Onglyza)
Linagliptin (FDA approved...
- Dapagliflozin/
saxagliptin, sold
under the
brand name Qtern, is a fixed-dose
combination anti-diabetic
medication used as an
adjunct to diet and exercise...
-
vildagliptin A10BD09
Pioglitazone and
alogliptin A10BD10
Metformin and
saxagliptin A10BD11
Metformin and
linagliptin A10BD12
Pioglitazone and sitagliptin...
- of oral anti-diabetics was
approved in 2019,
consisting of metformin,
saxagliptin, and dapagliflozin.
Another triple combination approval for metformin...
-
heart failure risk to
labels of type 2
diabetes medicines containing saxagliptin and alogliptin". U.S. Food and Drug
Administration (FDA).
Retrieved 16...
- Cagrilintide/semaglutide§ Dapagliflozin/metformin Dapagliflozin/
saxagliptin Dapagliflozin/
saxagliptin/metformin Empagliflozin/linagliptin Empagliflozin/metformin...
